As part of a diverse group of engineers and scientists partnering with St. Michael’s Hospital clinicians and researchers, Michael Kolios is using physics to create new methodologies that use ultrasound and optics to image and treat cancer.
The external,Institute for Biomedical Engineering, Science and Technology (iBEST) is a unique partnership between Ryerson University and St. Michael’s that brings together Ryerson’s engineering and science strengths with St. Michael’s biomedical research and clinical expertise to translate research concepts into real and testable health-care solutions.
Kolios’ research is paving the way for new cancer therapies that minimize damage to surrounding cells and make tumours more sensitive to other forms of treatment. It's also leading to more efficient and non-invasive ways to monitor treatment effectiveness, so doctors can see how well a patient is responding and make adjustments sooner. Ultimately, these therapies and methods are leading to better treatments and outcomes for people with cancer.
As co-director of iBEST, a position he shares with Sri Krishnan (Ryerson) and Dr. Ori Rotstein (St. Michael’s), Kolios is able to take learning out of the classroom and into the state-of-the-art labs and infrastructure at St. Michael’s. Through this unique setting, Ryerson students have the opportunity to conduct research that has a real and beneficial impact on patients. Students learn to use technology from experts, giving them the opportunity to deliver higher quality research and solutions.
This unique collaboration not only transforms the way health professionals and students collaborate, it leads to better and more effective ways to treat people with cancer.
Professor, Physics, Faculty of Science
Associate Dean, Research and Graduate Studies, Faculty of Science
Co-Director and Researcher, Institute for Biomedical Engineering, Science and Technology